First novel anti-tuberculosis drug in 40 years
On the last day of 2012, the US Food and Drug Administration (FDA) approved a new drug to treat tuberculosisthe first anti-mycobacterial compound with a novel mechanism of action in 40 years. The agencys go-ahead is for Sirturo (bedaquiline), a diarylquinoline (DARQ) antibiotic, to be dispensed as p...
Gespeichert in:
| Veröffentlicht in: | Nature biotechnology 2013-02, Vol.31 (2), p.89-90 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 90 |
|---|---|
| container_issue | 2 |
| container_start_page | 89 |
| container_title | Nature biotechnology |
| container_volume | 31 |
| creator | Osborne, Randy |
| description | On the last day of 2012, the US Food and Drug Administration (FDA) approved a new drug to treat tuberculosisthe first anti-mycobacterial compound with a novel mechanism of action in 40 years. The agencys go-ahead is for Sirturo (bedaquiline), a diarylquinoline (DARQ) antibiotic, to be dispensed as part of combination therapy in cases of multidrug resistance tuberculosis (MDR-TB) when other alternatives are not available. The accelerated approval was based on phase 2 data from 394 patients (a follow-up phase 3 trial is slated for this year). It marks an important breakthrough for the treatment of MDR-TB and is the first of several other compounds with novel mechanisms progressing in the pipeline. |
| doi_str_mv | 10.1038/nbt0213-89 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1285461543</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A320857591</galeid><sourcerecordid>A320857591</sourcerecordid><originalsourceid>FETCH-LOGICAL-c523t-30740bc8791fb005c985b979f19a5dd7f622aa3333d8393baa816e0b237fb6423</originalsourceid><addsrcrecordid>eNqN0ktPHSEUAGDS1NRHu_EHNJN0U6tzy2NgYGlMbU1MTPraEphhppi5jHKg0X8v9t623uqikACB75wAOQjtE7wgmMn3wSZMCauleoZ2CG9ETYQSz8say7bGhItttAtwiTEWjRAv0DZlTNFG8h20OPURUhXmn26qTEi-Ttm62OVpBg9VH_NY-VA1uLp1JsJLtDWYCdyr9byHvp1--HryqT6_-Hh2cnxed5yyVDPcNth2slVksBjzTkluVasGogzv-3YQlBrDSuslU8waI4lw2FLWDlY0lO2ht6u8V3G-zg6SXnro3DSZ4OYMmlBZ3lneygp98w-9nHMM5Xa_FOGUUvlXjWZy2odhTtF090n1MaNY8pYrUtTiCVV675a-m4MbfNnfCDjYCCgmuZs0mgygz758_n978X3THj2wNoMPDsoAfvyRYBWywd-teBdngOgGfRX90sRbTbC-rxG9rhEtVcGv1x-W7dL1f-jvoijgcAWgHIXRxQc_-jjdHewdvl4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1285152228</pqid></control><display><type>article</type><title>First novel anti-tuberculosis drug in 40 years</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><creator>Osborne, Randy</creator><creatorcontrib>Osborne, Randy</creatorcontrib><description>On the last day of 2012, the US Food and Drug Administration (FDA) approved a new drug to treat tuberculosisthe first anti-mycobacterial compound with a novel mechanism of action in 40 years. The agencys go-ahead is for Sirturo (bedaquiline), a diarylquinoline (DARQ) antibiotic, to be dispensed as part of combination therapy in cases of multidrug resistance tuberculosis (MDR-TB) when other alternatives are not available. The accelerated approval was based on phase 2 data from 394 patients (a follow-up phase 3 trial is slated for this year). It marks an important breakthrough for the treatment of MDR-TB and is the first of several other compounds with novel mechanisms progressing in the pipeline.</description><identifier>ISSN: 1087-0156</identifier><identifier>EISSN: 1546-1696</identifier><identifier>DOI: 10.1038/nbt0213-89</identifier><identifier>PMID: 23392485</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>631/154/155 ; 692/308/153 ; 692/699/255/1856 ; Agriculture ; Antitubercular Agents - therapeutic use ; Bioinformatics ; Biomedical and Life Sciences ; Biomedical Engineering/Biotechnology ; Biomedicine ; Biotechnology ; Drug therapy ; FDA approval ; Humans ; Licensing, certification and accreditation ; Life Sciences ; Mitochondrial Proton-Translocating ATPases - antagonists & inhibitors ; Mycobacterium tuberculosis - enzymology ; Mycobacterium tuberculosis - pathogenicity ; news ; Pharmaceutical industry ; Product development ; Tuberculosis ; Tuberculosis - drug therapy ; Tuberculosis - epidemiology ; Tuberculosis - microbiology</subject><ispartof>Nature biotechnology, 2013-02, Vol.31 (2), p.89-90</ispartof><rights>Springer Nature America, Inc. 2013</rights><rights>COPYRIGHT 2013 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Feb 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c523t-30740bc8791fb005c985b979f19a5dd7f622aa3333d8393baa816e0b237fb6423</citedby><cites>FETCH-LOGICAL-c523t-30740bc8791fb005c985b979f19a5dd7f622aa3333d8393baa816e0b237fb6423</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/nbt0213-89$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/nbt0213-89$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23392485$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Osborne, Randy</creatorcontrib><title>First novel anti-tuberculosis drug in 40 years</title><title>Nature biotechnology</title><addtitle>Nat Biotechnol</addtitle><addtitle>Nat Biotechnol</addtitle><description>On the last day of 2012, the US Food and Drug Administration (FDA) approved a new drug to treat tuberculosisthe first anti-mycobacterial compound with a novel mechanism of action in 40 years. The agencys go-ahead is for Sirturo (bedaquiline), a diarylquinoline (DARQ) antibiotic, to be dispensed as part of combination therapy in cases of multidrug resistance tuberculosis (MDR-TB) when other alternatives are not available. The accelerated approval was based on phase 2 data from 394 patients (a follow-up phase 3 trial is slated for this year). It marks an important breakthrough for the treatment of MDR-TB and is the first of several other compounds with novel mechanisms progressing in the pipeline.</description><subject>631/154/155</subject><subject>692/308/153</subject><subject>692/699/255/1856</subject><subject>Agriculture</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Bioinformatics</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedical Engineering/Biotechnology</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Drug therapy</subject><subject>FDA approval</subject><subject>Humans</subject><subject>Licensing, certification and accreditation</subject><subject>Life Sciences</subject><subject>Mitochondrial Proton-Translocating ATPases - antagonists & inhibitors</subject><subject>Mycobacterium tuberculosis - enzymology</subject><subject>Mycobacterium tuberculosis - pathogenicity</subject><subject>news</subject><subject>Pharmaceutical industry</subject><subject>Product development</subject><subject>Tuberculosis</subject><subject>Tuberculosis - drug therapy</subject><subject>Tuberculosis - epidemiology</subject><subject>Tuberculosis - microbiology</subject><issn>1087-0156</issn><issn>1546-1696</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>N95</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0ktPHSEUAGDS1NRHu_EHNJN0U6tzy2NgYGlMbU1MTPraEphhppi5jHKg0X8v9t623uqikACB75wAOQjtE7wgmMn3wSZMCauleoZ2CG9ETYQSz8say7bGhItttAtwiTEWjRAv0DZlTNFG8h20OPURUhXmn26qTEi-Ttm62OVpBg9VH_NY-VA1uLp1JsJLtDWYCdyr9byHvp1--HryqT6_-Hh2cnxed5yyVDPcNth2slVksBjzTkluVasGogzv-3YQlBrDSuslU8waI4lw2FLWDlY0lO2ht6u8V3G-zg6SXnro3DSZ4OYMmlBZ3lneygp98w-9nHMM5Xa_FOGUUvlXjWZy2odhTtF090n1MaNY8pYrUtTiCVV675a-m4MbfNnfCDjYCCgmuZs0mgygz758_n978X3THj2wNoMPDsoAfvyRYBWywd-teBdngOgGfRX90sRbTbC-rxG9rhEtVcGv1x-W7dL1f-jvoijgcAWgHIXRxQc_-jjdHewdvl4</recordid><startdate>20130201</startdate><enddate>20130201</enddate><creator>Osborne, Randy</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>N95</scope><scope>XI7</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20130201</creationdate><title>First novel anti-tuberculosis drug in 40 years</title><author>Osborne, Randy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c523t-30740bc8791fb005c985b979f19a5dd7f622aa3333d8393baa816e0b237fb6423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>631/154/155</topic><topic>692/308/153</topic><topic>692/699/255/1856</topic><topic>Agriculture</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Bioinformatics</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedical Engineering/Biotechnology</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Drug therapy</topic><topic>FDA approval</topic><topic>Humans</topic><topic>Licensing, certification and accreditation</topic><topic>Life Sciences</topic><topic>Mitochondrial Proton-Translocating ATPases - antagonists & inhibitors</topic><topic>Mycobacterium tuberculosis - enzymology</topic><topic>Mycobacterium tuberculosis - pathogenicity</topic><topic>news</topic><topic>Pharmaceutical industry</topic><topic>Product development</topic><topic>Tuberculosis</topic><topic>Tuberculosis - drug therapy</topic><topic>Tuberculosis - epidemiology</topic><topic>Tuberculosis - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Osborne, Randy</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Business: Insights</collection><collection>Business Insights: Essentials</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Osborne, Randy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First novel anti-tuberculosis drug in 40 years</atitle><jtitle>Nature biotechnology</jtitle><stitle>Nat Biotechnol</stitle><addtitle>Nat Biotechnol</addtitle><date>2013-02-01</date><risdate>2013</risdate><volume>31</volume><issue>2</issue><spage>89</spage><epage>90</epage><pages>89-90</pages><issn>1087-0156</issn><eissn>1546-1696</eissn><abstract>On the last day of 2012, the US Food and Drug Administration (FDA) approved a new drug to treat tuberculosisthe first anti-mycobacterial compound with a novel mechanism of action in 40 years. The agencys go-ahead is for Sirturo (bedaquiline), a diarylquinoline (DARQ) antibiotic, to be dispensed as part of combination therapy in cases of multidrug resistance tuberculosis (MDR-TB) when other alternatives are not available. The accelerated approval was based on phase 2 data from 394 patients (a follow-up phase 3 trial is slated for this year). It marks an important breakthrough for the treatment of MDR-TB and is the first of several other compounds with novel mechanisms progressing in the pipeline.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>23392485</pmid><doi>10.1038/nbt0213-89</doi><tpages>2</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-0156 |
| ispartof | Nature biotechnology, 2013-02, Vol.31 (2), p.89-90 |
| issn | 1087-0156 1546-1696 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1285461543 |
| source | MEDLINE; SpringerLink Journals; Nature Journals Online |
| subjects | 631/154/155 692/308/153 692/699/255/1856 Agriculture Antitubercular Agents - therapeutic use Bioinformatics Biomedical and Life Sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Drug therapy FDA approval Humans Licensing, certification and accreditation Life Sciences Mitochondrial Proton-Translocating ATPases - antagonists & inhibitors Mycobacterium tuberculosis - enzymology Mycobacterium tuberculosis - pathogenicity news Pharmaceutical industry Product development Tuberculosis Tuberculosis - drug therapy Tuberculosis - epidemiology Tuberculosis - microbiology |
| title | First novel anti-tuberculosis drug in 40 years |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T13%3A38%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First%20novel%20anti-tuberculosis%20drug%20in%2040%20years&rft.jtitle=Nature%20biotechnology&rft.au=Osborne,%20Randy&rft.date=2013-02-01&rft.volume=31&rft.issue=2&rft.spage=89&rft.epage=90&rft.pages=89-90&rft.issn=1087-0156&rft.eissn=1546-1696&rft_id=info:doi/10.1038/nbt0213-89&rft_dat=%3Cgale_proqu%3EA320857591%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1285152228&rft_id=info:pmid/23392485&rft_galeid=A320857591&rfr_iscdi=true |